Cullinan Therapeutics Inc (CGEM)
17.97
+0.04
(+0.22%)
USD |
NASDAQ |
Sep 06, 16:00
17.98
+0.01
(+0.06%)
After-Hours: 20:00
Cullinan Therapeutics Research and Development Expense (Annual): 148.16M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 148.16M |
| December 31, 2022 | 91.95M |
| December 31, 2021 | 57.75M |
| Date | Value |
|---|---|
| December 31, 2020 | 43.21M |
| December 31, 2019 | 16.79M |
| December 31, 2018 | 9.584M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
16.79M
Minimum
2019
148.16M
Maximum
2023
71.57M
Average
57.75M
Median
2021
Research and Development Expense (Annual) Benchmarks
| CEL-SCI Corp | 22.47M |
| AIM ImmunoTech Inc | 10.94M |
| IGC Pharma Inc | 3.773M |
| NovaBay Pharmaceuticals Inc | 0.068M |
| Protalix BioTherapeutics Inc | 17.09M |